Financial Data and Key Metrics Changes - Q1 2025 revenue totaled $9,300,000, representing a 61% increase compared to $5,800,000 in Q1 2024, exceeding previous guidance of 45% to 55% growth [14][17] - Gross margin improved to 79% in Q1 2025 from 72.6% in Q1 2024, an increase of over 640 basis points attributed to reduced production costs and strategic pricing [15] - Operating income for Q1 2025 was $1,000,000, an improvement of $2,000,000 year-over-year [15] - Net loss for Q1 2025 was $5,700,000, compared to a net loss of $4,500,000 in Q1 2024, primarily due to higher non-cash expenses [16] - Adjusted EBITDA for Q1 2025 was positive $2,300,000, an improvement of $2,400,000 year-over-year [16] Business Line Data and Key Metrics Changes - The company placed 98 new Ultomis systems in Q1 2025, a 128% increase from 43 systems in Q1 2024 [7] - Applicator sales were $5,800,000 in Q1 2025, up from $4,100,000 in Q1 2024, constituting 62% of total revenues [8][9] - The company ended the quarter with 1,145 systems in the field, with 429 placed in the trailing twelve months [7] Market Data and Key Metrics Changes - The company is experiencing a seasonal pattern where patients delay treatment in Q1 due to out-of-pocket maximum resets, leading to reduced usage until Q2 [9] - The company is focusing on engaging larger customers and has been building inventory to support this strategy [10][11] Company Strategy and Development Direction - The company aims to continue its growth strategy with a guidance of $10,000,000 to $10,700,000 in Q2 revenues, reflecting 40% to 50% year-on-year growth [18] - The sales strategy focuses on engaging larger customers and expanding into mobile and home healthcare markets [44][46] - The company is exploring refinancing opportunities to improve its debt situation [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the supply chain and manufacturing capabilities, stating no anticipated material cost or margin issues from current economic conditions [11] - The company is optimistic about building on the momentum from Q1 and executing its growth strategy [17] Other Important Information - The company incurred a $295,000 listing fee for its NASDAQ uplift, impacting operating profit and EBITDA figures [12] - The company has been stockpiling longer lead-time components to enable rapid production ramp-up if needed [10] Q&A Session Summary Question: Can you quantify system placements from smaller and larger customers? - Management noted the complexity in categorizing customers, stating 58 new customers were added in Q1, with growth potential varying among them [24] Question: What is the typical time to sale from initiation to purchase order? - Management indicated a wide range, from a couple of days for smaller orders to several months for larger customers [28] Question: Can you address the debt landscape? - Management acknowledged the high cost of debt and mentioned exploring refinancing opportunities [33] Question: What is the success rate within the total addressable market? - Management stated they do not have clear visibility into specific treatments due to HIPAA regulations but are in contact with providers to understand applications [36] Question: Any updates on patent assertion suits? - Management confirmed an intellectual property assertion agreement with an outside firm, expressing satisfaction with progress but noting the private nature of the process [39] Question: Insight into the evolving sales strategy? - Management highlighted a focus on engaging larger customers and the importance of experienced sales executives in the strategy [44]

Financial Data and Key Metrics Changes - In Q1 2025, the company reported a net income of $20.5 million and operating income of $69.4 million, with net cash provided by operating activities at $54.7 million [12] - The average revenue per horsepower reached an all-time high of $21.6, reflecting a 1% increase sequentially and a 6% increase year-over-year [12] - The adjusted gross margin for Q1 was nearly 67%, consistent with previous quarters [12][14] Business Line Data and Key Metrics Changes - The total fleet horsepower at the end of Q1 was approximately 3.9 million horsepower, unchanged from the prior quarter, while revenue-generating horsepower was flat sequentially but up 2% year-over-year [13] - Average utilization for the first quarter was 94.4%, slightly down from 94.5% in the prior quarter [13] Market Data and Key Metrics Changes - The company holds the largest contract compression fleet in the Northeast, totaling around 900,000 horsepower, benefiting from strong demand in the data center market [7][8] - Key upstream companies in the Permian and Northeast reaffirmed their full-year capital production targets despite softening commodity prices [7] Company Strategy and Development Direction - The company is focused on disciplined growth, particularly in acquiring large horsepower, while monitoring market conditions closely [6][10] - The transition of IT and HR functions has been completed, with an ERP implementation planned for Q1 2026 to improve business management [11] Management's Comments on Operating Environment and Future Outlook - Management noted that while commodity prices have softened, the compression business is sustained by long-term agreements, making it less susceptible to short-term price fluctuations [10] - The company anticipates maintaining adjusted operating margins around 67% and is committed to reducing its leverage ratio while funding new growth projects [14][15] Other Important Information - The company has completed its idle to active initiative, with large horsepower utilization remaining close to fully utilized [6] - A promotion of Chris Wasson to Chief Operating Officer was highlighted, recognizing his leadership in the Permian operations [10] Q&A Session Summary Question: Guidance for 2025 - Management confirmed maintaining the guidance range of $590 million to $610 million for adjusted EBITDA, with Q1 performance aligning with the midpoint of this range [20][21] Question: Growth Outlook Beyond 2025 - Management indicated strong interest in 2026 proposals, with ongoing discussions and RFPs being undertaken despite current macroeconomic uncertainties [22][24] Question: Operating Horsepower Growth - The addition of 40,000 horsepower in Q1 was noted as below the full-year forecast, but management expressed confidence in meeting year-end targets [27][28] Question: Contracting Environment - Management stated that there has not been a significant change in contract duration or terms, with a preference for longer-term agreements to mitigate risks [36][37] Question: Lead Times and Manufacturing - Lead times for equipment remain stable, with no significant changes expected unless tariffs impact the market [38][39] Question: Asset Sales and Portfolio Optimization - Management confirmed ongoing efforts to optimize the portfolio through modest asset sales and swaps, aiming to improve overall efficiency [42][43]

Financial Data and Key Metrics Changes - Adjusted EBITDA for 2024 was $127.6 million, up from $107.5 million in 2023, marking more than a doubling over the past two years [9] - The company anticipates total annual EBITDA of approximately $323 million, combining 2024 results with $195 million of incremental locked-in annual EBITDA under executed contracts [10] - The target for annual EBITDA is estimated to exceed $400 million, significantly higher than the previous target of just over $300 million [11] Business Line Data and Key Metrics Changes - Transtar reported Q4 revenue of $43.3 million and adjusted EBITDA of $19.4 million, compared to $44.8 million and $21.1 million in Q3 [26] - Jefferson generated $21.2 million in revenue and $11.1 million in adjusted EBITDA in Q4, up from $19.7 million and $11.8 million in Q3, excluding a one-time asset sale gain [29] - Long Ridge's EBITDA in Q4 was $9.9 million, down from $11.1 million in Q3, due to a planned maintenance outage [34] Market Data and Key Metrics Changes - The company is pursuing more new business opportunities than at any time since its spin-off, indicating a strong pipeline for growth [10] - The M&A market is described as the most active in years, with discussions on six opportunities representing well over $100 million of annual EBITDA [16][28] Company Strategy and Development Direction - The company plans to focus on substantial growth in 2025, with specific initiatives at Long Ridge, Repauno, and Jefferson [11][12][14] - Long Ridge's recent transactions are expected to enhance earnings significantly, allowing the company to capture 100% of the value creation [22] - The company is evaluating multiple products and counterparties at Jefferson, including crude oil, natural gas liquids, and renewables [41][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving substantial growth in 2025, driven by new contracts and business opportunities [11][12] - The anticipated increase in capacity payments and demand for power from hyperscalers is expected to positively impact Long Ridge's financials [36] - Management remains optimistic about the potential for M&A opportunities and the ability to finance acquisitions through debt markets [90] Other Important Information - The company has received approval for $300 million of tax-exempt debt, providing access to low-cost, long-term capital for construction projects [14] - The refinancing of corporate bonds and existing preferred stock is planned for the second quarter, aimed at reducing fixed charges and increasing cash flow [25][58] Q&A Session Summary Question: Expansion on new deals at Jefferson - Management is negotiating various products including crude oil, natural gas liquids, and renewables, with significant potential for growth [41][46] Question: Timing for Long Ridge's $160 million EBITDA - The full impact of the $160 million EBITDA from Long Ridge will be reflected in Q3, with partial contributions in Q1 and Q2 [48][50] Question: Update on Repauno permits and Phase 3 potential - Permits for the underground cavern are expected by the end of Q1, with Phase 3 potentially generating an incremental $100 million of EBITDA [62][64] Question: Transtar's organic growth target - Management remains confident in achieving a 15% organic growth rate, supported by anticipated increases in production levels [66][69] Question: M&A activity and financing - The company is evaluating several M&A opportunities and expects to announce a transaction within the next three months, with financing planned through debt markets [72][90]